Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

Computational Chemistry: A Tool for Feeding R&D Pipelines 10/26/2006 \| published by: Decision Resources ... both to pharmaceutical companies that use these tools effectively and to software companies that provide them. Get the Answers You Need to Shape Your Strategy Computational tools will feature in a new drug discovery paradigm ... \| more...	$1,112.50
Emerging Diagnostic Biomarkers in Ovarian Cancer 7/20/2006 \| published by: Decision Resources ... of CaO will be diagnosed in the United States and 15,310 women will die from the disease. This high death rate results from the difficulty associated with detecting CaO at an early stage and the ... \| more...	$1,112.50
Medicare Part D: Strategies of the Leading Health Plans 6/30/2006 \| published by: Decision Resources ... only limited coverage of prescription medicines. To improve beneficiaries' access to outpatient prescription medicines, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (commonly known as the Medicare Modernization Act, or MMA) introduced Medicare ... \| more...	$1,112.50
Pharmaceutical Pricing, Reimbursement Environment in China 11/15/2006 \| published by: Decision Resources ... controls, extensive retail mark-ups, and wide regional variations in insurance all pose specific challenges for companies looking to enter the Chinese market. Get the Answers You Need to Shape Your Strategy The Chinese government still ... \| more...	$1,112.50
Parkinson’s Disease Biomarkers: Vital Tools for Neuroprotectants 11/20/2006 \| published by: Decision Resources ... million in 2015, yet no therapy is available to treat the disease. Thus, the PD market provides signifi cant opportunity for disease-modifying drugs, but their potential will not be fully realized without a biomarker that ... \| more...	$1,112.50
Blockbusters Are Alive and Well: Why Their Numbers Continue to Rise 11/17/2006 \| published by: Decision Resources ... grown continuously, and this growth shows no signs of a slowdown. Get the Answers You Need to Shape Your Strategy- Specialist-oriented products now account for a growing share of blockbuster drugs. How will this changing ... \| more...	$1,112.50
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007 9/10/2007 \| published by: Decision Resources ... the United States, Medicare Part D's growing share of the U.S. prescription drug market could be bad news for pharmaceutical companies because employer-sponsored health plans typically offer more generous drug benefi t designs. The French ... \| more...	$1,112.50
Value-Added Pharma: How to Accomplish the Impossible 11/20/2008 \| published by: Decision Resources ... wider use of generics-all of which translates into more value at reasonable cost (the value-added proposition). But how does the industry transform itself from where it is now to where it needs to be-how does ... \| more...	$1,125.00
Effective Drug Life Cycle Management: The Crucial Interaction Between Brand Life Span and Market Life Cycle 9/30/2008 \| published by: Decision Resources ... of the brand life span relate to the four stages of the market life cycle. The challenges increase as markets approach the mature and declining stages and generics competition looms. Follow-on products can offer a ... \| more...	$1,125.00
Key Issues to Consider When Bringing Biologics to Market in Europe and Japan 7/28/2008 \| published by: Decision Resources ... force in Europe and Japan, where they are well represented in companies' product pipelines. Issues that will make or break the successful integration of biologics in European and Japanese biopharmaceutical market include clinical trial design, ... \| more...	$1,125.00
Noninvasive Approaches Offer Substantial Market Potential in Liver Disease Diagnostics 7/17/2008 \| published by: Decision Resources ... perceptions of noninvasive approaches, gathered in a series of interviews with leading hepatologists. We provide a general view of the market potential for noninvasive liver diagnostics and the challenges and opportunities for companies seeking to ... \| more...	$1,125.00
Asia: Threat or Opportunity? 5/5/2008 \| published by: Decision Resources ... offer. Cost cutting alone, however, should not be the sole reason for multinational companies (MNCs) to outsource activities to Southeast Asia. Companies must make the effort to understand the local culture and business environment in ... \| more...	$1,125.00
Pharmaceutical Pricing and Reimbursement in Italy, 2008 5/7/2008 \| published by: Decision Resources ... the global market will be severely compromised, and Italy will soon be overtaken in the global rankings by other major pharmaceutical markets. Get the Answers You Need to Shape Your Strategy The Italian government has ... \| more...	$1,125.00
The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends 6/5/2008 \| published by: Decision Resources ... drug because of their particular metabolic activity. The concept of companion diagnostics as an integral component of personalized medicine-RxDx-is an emerging and critical paradigm for drug development and use. What is driving that paradigm? Get ... \| more...	$1,125.00
Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market 5/7/2008 \| published by: Decision Resources ... to explore unconventional strategies that will minimize the resources necessary to ensure success in OCD. Get the Answers You Need to Shape Your Strategy Despite the high use of drug therapy in the treatment of ... \| more...	$1,125.00
Product Life Spans: Trends in the Quality and Staying Power of New Products 6/5/2008 \| published by: Decision Resources ... forecasts, but a key element in these projections concerns the product's staying power or longevity. In this report, we provide a logical analysis based on 12 years of data (1994 to 2006) to support a ... \| more...	$1,125.00
Emerging Diagnostic Technologies for Use in Psychiatric Indications 5/29/2008 \| published by: Decision Resources ... of a psychiatric disease and even direct potential drug therapy. In this report, we discuss the treatment challenges that confront physicians and patients and review current and emerging diagnostic tests that are expected to change ... \| more...	$1,125.00
Improving Return on Investment in Pharmaceutical Marketing 6/17/2008 \| published by: Decision Resources ... at almost twice the spend of R&D. How can companies improve their return on investment (ROI)? We propose a three-tiered approach to improve the value of pharmaceutical marketing investments by increasing ROI. Get the Answers ... \| more...	$1,125.00
How Have Safety Concerns and New Warnings Affected the Anemia Market? 6/26/2008 \| published by: Decision Resources ... and reimbursement, and significant decline in ESA sales ensued. Can the market survive this crisis and return to prosperity? Get the Answers You Need to Shape Your Strategy Concerns about the safety of ESAs have ... \| more...	$1,125.00
Pharmaceutical Pricing and Reimbursement in France, 2008 6/11/2008 \| published by: Decision Resources ... may have to pursue more radical reform in the future, and the pharmaceutical industry will have to adapt to a market that places growing emphasis on the costeffectiveness of treatments. Get the Answers You Need ... \| more...	$1,125.00
Key Trends in the Political and Reimbursement Environment for Cancer Drugs 3/26/2008 \| published by: Decision Resources ... 2010. Not surprisingly, the pharmaceutical industry is eager to tap the potential of this market. A critical factor in this growth, in both the United States and the European market, is the ever-evolving reimbursement environment-and ... \| more...	$1,150.00
Pricing and Reimbursement of Targeted Cancer Therapies 12/15/2009 \| published by: Decision Resources ... on these agents is forcing governments and private health insurers to reassess their reimbursement strategies for cancer therapies. In an increasingly cost-conscious environment, pharmaceutical companies must fi nd new ways to justify the cost of ... \| more...	$1,150.00
Pharma's Changing Business Strategies: Five Deadly Pharma Sins 10/30/2008 \| published by: Decision Resources ... going to be like the past and that something needs to be done to fundamentally change pharma's business strategies-and fast. The case studies in this report describe management-driven changes currently under way in three leading ... \| more...	$1,668.75
Opportunities in Noninvasive Prenatal Diagnostics and Newborn Screening 2/1/2011 \| published by: Decision Resources ... Next-generation sequencing techniques coupled with molecular assays are at the forefront of the genetic testing boom, with the singular aim of optimally isolating fetal DNA. It is at this juncture within the molecular diagnostic testing ... \| more...	$1,725.00
Biologics/Biosimilars in Immune and Inflammatory Disease: Will Novel Biologics and Biosimilars Disrupt Competitive Markets? 12/1/2010 \| published by: Decision Resources ... developers to seek further opportunities for biologics in immune/inflammatory diseases, especially in the treatment of patients who fail to respond adequately to currently available biologics as well as small-molecule therapies. Questions Answered Small molecules command ... \| more...	$1,725.00

< prev 1 2 3 4 5 6 7 8 9 10 next >